ChinaDaily Briefs

Daily Brief China: L’Occitane, ESR Group , ASM Pacific Technology, Chow Tai Fook Jewellery, Shanghai Junshi Biosciences , JD Logistics and more

In today’s briefing:

  • (Mostly) Asia-Pac M&A: Sermsuk, L’Occitane, Shinko Electric, MMA Offshore, Hollysys
  • Weekly Deals Digest (07 Jul) – ESR, L’Occitane, Hollysys, Aisin, Honda, Sanil, Shift Up, Timee
  • Quiddity Leaderboard HSTECH Sep 24: Reference Period Over; One Change Likely; US$733mn One-Way
  • Asian Dividend Gems: Chow Tai Fook Jewellery
  • China Healthcare Weekly (July.7) – MNCs’ Next Move In Licensing Deals, Topchoice, Junshi’s Trouble
  • Quiddity Leaderboard HSCEI Sep 24: Final Ranks and Updated Flow Expectations


(Mostly) Asia-Pac M&A: Sermsuk, L’Occitane, Shinko Electric, MMA Offshore, Hollysys

By David Blennerhassett


Weekly Deals Digest (07 Jul) – ESR, L’Occitane, Hollysys, Aisin, Honda, Sanil, Shift Up, Timee

By Arun George


Quiddity Leaderboard HSTECH Sep 24: Reference Period Over; One Change Likely; US$733mn One-Way

By Janaghan Jeyakumar, CFA

  • The HSTECH Index tracks the performance of the top 30 technology companies listed in Hong Kong that have high business exposure to certain technology themes.
  • The reference period for the September 2024 index rebal event is now complete. In this insight, we take a look at our final expectations for index changes.
  • Our current estimates suggest one-way flows due to index changes and capping could be around US$733mn but that could change by early September 2024.

Asian Dividend Gems: Chow Tai Fook Jewellery

By Douglas Kim

  • Chow Tai Fook Jewellery’s shares are down 28.2% YTD, sharply underperforming the Hang Seng Index which is up 6% in the same period. We believe this divergence is excessive. 
  • Chow Tai Fook’s dividend yield averaged 4.8% from FY20 to FY24. Its annual dividend payout averaged 107% in the same period.
  • Chai Tai Fook is currently trading at attractive valuations. It is trading at P/E of 10.1x, EV/EBITDA of 7.5x, and P/B of 2.9x based on FY25 consensus earnings estimates. 

China Healthcare Weekly (July.7) – MNCs’ Next Move In Licensing Deals, Topchoice, Junshi’s Trouble

By Xinyao (Criss) Wang

  • For all licensing cooperation with MNCs, we recommend that investors wait to see what MNCs’ next move is before deciding whether the cooperation is really promising.
  • Topchoice showed good business growth in 24Q2. Our biggest concern for Topchoice is that the unit price per customer may further decrease in the future, thereby affecting revenue/profit growth.
  • Junshi’s sales growth picked up in 24Q1, but concerns on Junshi persist. We don’t think Junshi is undervalued and its valuation should be lower than that of peers.

Quiddity Leaderboard HSCEI Sep 24: Final Ranks and Updated Flow Expectations

By Janaghan Jeyakumar, CFA

  • The HSCEI serves as a benchmark to reflect the overall performance of the top 50 “Mainland China” securities listed in Hong Kong.
  • In mid-June 2024, we had two expected ADDs and DELs for the September 2024 index rebal event and they remain unchanged even after the end of the reference period.
  • However, our capping flow expectations continue to change as the pro-forma post-rebalance weights change with share prices. In this insight, we have provided our latest flow estimates.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars